{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:39:19Z","timestamp":1761561559101},"reference-count":50,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:p>Existing monotherapies for the treatment of obesity provide only modest weight loss and\/or have adverse side effects, and this is also the case with the cannabinoid receptor 1 (CB1) inverse agonist, rimonabant. We aimed to investigate the possibility of improving efficacy and reducing side effects of rimonabant by cotreatment with opioid system antagonists. Using both genetic and pharmacological removal of opioid signaling in mice, we investigated changes in body weight, food intake, and fat mass as well as behavioral outcomes of interactions between opioid ligands and the CB1 using the inverse agonist, rimonabant. The ability of rimonabant to reduce weight is enhanced by removal of with \u03bc-opioid receptor signaling, while not being greatly affected by \u03ba-opioid receptor blockade. Additionally, lack of opioid signaling, especially \u03ba-opioid receptor, attenuated the ability of rimonabant to decrease immobility time in the Porsolt forced-swim test, a preclinical model of depression. These results indicate that the endogenous opioid system is involved in modulating both the metabolic and mood effects of rimonabant.<\/jats:p>","DOI":"10.1210\/en.2011-1220","type":"journal-article","created":{"date-parts":[[2011,8,3]],"date-time":"2011-08-03T02:40:31Z","timestamp":1312339231000},"page":"3661-3667","source":"Crossref","is-referenced-by-count":22,"title":["CNS Opioid Signaling Separates Cannabinoid Receptor 1-Mediated Effects on Body Weight and Mood-Related Behavior in Mice"],"prefix":"10.1210","volume":"152","author":[{"given":"Sarah Haas","family":"Lockie","sequence":"first","affiliation":[{"name":"Metabolic Diseases Institute (S.H.L., N.C., D.P.-T., M.H.T.), University of Cincinnati, Cincinnati, Ohio 45237"},{"name":"Department of Physiology (S.H.L., B.J.O.), Monash University, Clayton, Victoria, Australia 3800"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci A.","family":"Czyzyk","sequence":"additional","affiliation":[{"name":"Eli Lilly and Co. (T.A.C., M.A.S.), Indianapolis, Indiana 46285"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilika","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Institute (S.H.L., N.C., D.P.-T., M.H.T.), University of Cincinnati, Cincinnati, Ohio 45237"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Perez-Tilve","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Institute (S.H.L., N.C., D.P.-T., M.H.T.), University of Cincinnati, Cincinnati, Ohio 45237"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Woods","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine and Department of Psychiatry (S.C.W.), University of Cincinnati, Cincinnati, Ohio 45237"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Oldfield","sequence":"additional","affiliation":[{"name":"Department of Physiology (S.H.L., B.J.O.), Monash University, Clayton, Victoria, Australia 3800"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Statnick","sequence":"additional","affiliation":[{"name":"Eli Lilly and Co. (T.A.C., M.A.S.), Indianapolis, Indiana 46285"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias H.","family":"Tsch\u00f6p","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Institute (S.H.L., N.C., D.P.-T., M.H.T.), University of Cincinnati, Cincinnati, Ohio 45237"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"key":"2020071613322082800_B1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrd2136","article-title":"The obesity pipeline: current strategies in the development of anti-obesity drugs.","volume":"5","author":"Cooke","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2020071613322082800_B2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1381\/096089206778026316","article-title":"Systematic review of medium-term weight loss after bariatric operations.","volume":"16","author":"O'Brien","year":"2006","journal-title":"Obes Surg"},{"key":"2020071613322082800_B3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0024-3205(95)00174-5","article-title":"Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.","volume":"56","author":"Rinaldi-Carmona","year":"1995","journal-title":"Life Sci"},{"key":"2020071613322082800_B4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","article-title":"The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.","volume":"7","author":"Addy","year":"2008","journal-title":"Cell Metab"},{"key":"2020071613322082800_B5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.phrs.2009.04.004","article-title":"The endocannabinoid system: role in glucose and energy metabolism.","volume":"60","author":"Nogueiras","year":"2009","journal-title":"Pharmacol Res"},{"key":"2020071613322082800_B6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1467-789X.2009.00581.x","article-title":"Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.","volume":"10","author":"Johansson","year":"2009","journal-title":"Obesity Rev [Erratum (2009)10:586]"},{"key":"2020071613322082800_B7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0031-9384(97)00101-7","article-title":"Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect.","volume":"62","author":"Yeomans","year":"1997","journal-title":"Physiol Behav"},{"key":"2020071613322082800_B8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1177\/009127009203201202","article-title":"Opiate antagonists and eating behavior in humans\u2014a review.","volume":"32","author":"de Zwaan","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"2020071613322082800_B9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0006-3223(87)90127-2","article-title":"High-dose naltrexone therapy and dietary counseling for obesity.","volume":"22","author":"Mitchell","year":"1987","journal-title":"Biol Psychiatry"},{"key":"2020071613322082800_B10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1210\/jcem-55-1-196","article-title":"Naloxone decreases food-intake in obese humans.","volume":"55","author":"Atkinson","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613322082800_B11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity.","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity"},{"key":"2020071613322082800_B12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1124\/jpet.107.127415","article-title":"Anxiolytic-Like effects of \u03ba-opioid receptor antagonists in models of unlearned and learned fear in rats.","volume":"323","author":"Knoll","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071613322082800_B13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of \u03ba-opioid receptor antagonists in the forced swim test in rats.","volume":"305","author":"Mague","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071613322082800_B14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/npp.2008.142","article-title":"Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone.","volume":"34","author":"Wittmann","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"2020071613322082800_B15","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.neuropharm.2005.01.022","article-title":"Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.","volume":"48","author":"Fattore","year":"2005","journal-title":"Neuropharmacology"},{"key":"2020071613322082800_B16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2005.09.039","article-title":"Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal \u0394(9)-tetrahydrocannabinol.","volume":"525","author":"Cichewicz","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"2020071613322082800_B17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2006.04.003","article-title":"Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by \u0394(9)-tetrahydrocannabinol.","volume":"539","author":"Williams","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"2020071613322082800_B18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainresrev.2005.10.004","article-title":"Cannabinoids, opioids and eating behavior: the molecular face of hedonism?","volume":"51","author":"Cota","year":"2006","journal-title":"Brain Res Rev"},{"key":"2020071613322082800_B19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1124\/jpet.106.101998","article-title":"Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of \u03ba-opioid receptor-1 knockout mice.","volume":"318","author":"Ansonoff","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071613322082800_B20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/5706","article-title":"Retention of heroin and morphine-6 \u03b2-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1.","volume":"2","author":"Schuller","year":"1999","journal-title":"Nat Neurosci"},{"key":"2020071613322082800_B21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0896-6273(00)80836-3","article-title":"Retention of supraspinal \u03b4-like analgesia and loss of morphine tolerance in \u03b4 opioid receptor knockout mice.","volume":"24","author":"Zhu","year":"1999","journal-title":"Neuron"},{"key":"2020071613322082800_B22","first-page":"30","article-title":"Nor-binaltorphimine\u2014a potent and selective \u03ba-opioid receptor antagonist with long-lasting activity in vivo.","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2020071613322082800_B23","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0024-3205(83)90665-3","article-title":"Brain and serum levels of naloxone following peripheral administration.","volume":"33","author":"Tepperman","year":"1983","journal-title":"Life Sci"},{"key":"2020071613322082800_B24","first-page":"327","article-title":"Behavioral despair in mice\u2014primary screening-test for antidepressants.","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2020071613322082800_B25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.npp.1300913","article-title":"Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice.","volume":"31","author":"Smith","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"2020071613322082800_B26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.physbeh.2008.12.013","article-title":"Long-term behavioral consequences of prenatal MDMA exposure.","volume":"96","author":"Thompson","year":"2009","journal-title":"Physiol Behav"},{"key":"2020071613322082800_B27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.105.092304","article-title":"Depressive-like effects of the \u03ba-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.","volume":"316","author":"Carlezon","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071613322082800_B28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bbr.2007.10.005","article-title":"Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food.","volume":"187","author":"Tallett","year":"2008","journal-title":"Behav Brain Res"},{"key":"2020071613322082800_B29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.neuropharm.2008.07.038","article-title":"Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.","volume":"55","author":"Wilson","year":"2008","journal-title":"Neuropharmacology"},{"key":"2020071613322082800_B30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00213-005-0114-4","article-title":"Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.","volume":"182","author":"Vigan\u00f2","year":"2005","journal-title":"Psychopharmacology"},{"key":"2020071613322082800_B31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1124\/jpet.102.046870","article-title":"Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral \u0394(9)-tetrahydrocannabinol.","volume":"305","author":"Cichewicz","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071613322082800_B32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0014-2999(02)02483-4","article-title":"Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404.","volume":"454","author":"Del Arco","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"2020071613322082800_B33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.peptides.2004.01.006","article-title":"Endogenous opioids and feeding behavior: a 30-year historical perspective.","volume":"25","author":"Bodnar","year":"2004","journal-title":"Peptides"},{"key":"2020071613322082800_B34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1096\/fj.09-143610","article-title":"\u03ba-Opioid receptors control the metabolic response to a high-energy diet in mice.","volume":"24","author":"Czyzyk","year":"2010","journal-title":"FASEB J"},{"key":"2020071613322082800_B35","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by \u03ba-opiate receptors.","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"2020071613322082800_B36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K","article-title":"Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study.","volume":"37","author":"Hohmann","year":"2000","journal-title":"Synapse"},{"key":"2020071613322082800_B37","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1073\/pnas.96.10.5786","article-title":"Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice.","volume":"96","author":"Steiner","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613322082800_B38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brainres.2006.03.088","article-title":"CB, knockout mice display significant changes in striatal opioid peptide and D-4 dopamine receptor gene expression.","volume":"1093","author":"Gerald","year":"2006","journal-title":"Brain Res"},{"key":"2020071613322082800_B39","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1523\/JNEUROSCI.22-03-01146.2002","article-title":"Motivational effects of cannabinoids are mediated by \u03bc-opioid and \u03ba-opioid receptors.","volume":"22","author":"Ghozland","year":"2002","journal-title":"J Neurosci"},{"key":"2020071613322082800_B40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.bjp.0705100","article-title":"The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.","volume":"138","author":"Tzavara","year":"2003","journal-title":"Br J Pharmacol"},{"key":"2020071613322082800_B41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejphar.2008.05.020","article-title":"Additive subthreshold dose effects of cannabinoid CB1 receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.","volume":"589","author":"Takahashi","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"2020071613322082800_B42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00176837","article-title":"Is the forced swimming test a suitable model for revealing antidepressant activity?","volume":"94","author":"Borsini","year":"1988","journal-title":"Psychopharmacology"},{"key":"2020071613322082800_B43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopsych.2007.07.020","article-title":"Involvement of \u03ba-opioid and endocannabinoid system on salvinorin A-induced reward.","volume":"63","author":"Braida","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2020071613322082800_B44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.drugalcdep.2010.05.003","article-title":"Use patterns and self-reported effects of Salvia divinorum An Internet-based survey.","volume":"111","author":"Baggott","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"2020071613322082800_B45","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1254\/jphs.08244FP","article-title":"\u03bc-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis.","volume":"108","author":"Hojo","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"2020071613322082800_B46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.neuropharm.2006.05.019","article-title":"Interactions between CB1 cannabinoid and \u03bc opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.","volume":"51","author":"Schoffelmeer","year":"2006","journal-title":"Neuropharmacology"},{"key":"2020071613322082800_B47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/138945010790980367","article-title":"Cellular mechanisms underlying the interaction between cannabinoid and opioid system.","volume":"11","author":"Parolaro","year":"2010","journal-title":"Curr Drug Targets"},{"key":"2020071613322082800_B48","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613322082800_B49","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1523\/JNEUROSCI.4331-05.2006","article-title":"Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location.","volume":"26","author":"Ford","year":"2006","journal-title":"J Neurosci"},{"key":"2020071613322082800_B50","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.","volume":"353","author":"Despr\u00e9s","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/152\/10\/3661\/9011091\/endo3661.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/152\/10\/3661\/9011091\/endo3661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:57:44Z","timestamp":1712671064000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/152\/10\/3661\/2457152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,2]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2011-1220","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,2]]}}}